Cargando…
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
BACKGROUND: Cognitive impairment affects many patients with multiple sclerosis (MS). NeuroTrax, a computerized cognitive screen that can be administered during routine clinical care, provides a consistent, validated, objective cognitive profile measure with a global cognitive score (GCS) and seven i...
Autores principales: | Gudesblatt, Mark, Wissemann, Karl, Zarif, Myassar, Bumstead, Barbara, Fafard, Lori, Wilken, Jeffrey, Blitz, Karen, Buhse, Marijean, Santra, Sourav, Hotermans, Christophe, Lee, Lily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280854/ https://www.ncbi.nlm.nih.gov/pubmed/30143944 http://dx.doi.org/10.1007/s40263-018-0553-1 |
Ejemplares similares
-
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
por: Perumal, Jai, et al.
Publicado: (2019) -
Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
por: Voloshyna, N, et al.
Publicado: (2015) -
Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008) -
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014) -
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)